Revance Shares Rally Premarket on FDA Expanded OK for Daxxify
By Colin Kellaher
Shares of Revance Therapeutics rose more than 10% in premarket trading Monday after the U.S. Food and Drug Administration approved the expanded use of its Daxxify antiwrinkle treatment in its first therapeutic indication.
The Nashville biotechnology company on Monday said the FDA approved Daxxify for the treatment of adults with cervical dystonia, a painful condition in which the neck muscles contract involuntarily.
Revance last year won FDA approval of Daxxify for the temporary improvement of frown lines in adults, launching a competitor to AbbVie's Botox antiwrinkle injection.
Revance said the approval of Daxxify for cervical dystonia gives the company entry into the $2.5 billion U.S. therapeutic neuromodulator market.
Revance shares, which closed Friday at $18.91, were recently up 11% to $21 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 14, 2023 08:54 ET (12:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase